(Q38633198)

5 September 2017

title

Combination therapy for type 2 diabetes: dapagliflozin plus metformin (English)

1 reference

5 September 2017

1 reference

1 reference

Xueying Tan

1

1 reference

5 September 2017

Jingbo Hu

series ordinal

2

1 reference

5 September 2017

language of work or name

English

0 references

publication date

15 November 2015

1 reference

Expert Opinion on Pharmacotherapy

5 September 2017

published in

1 reference

5 September 2017

volume

17

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

117-126

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Clinical practice. Glycemic management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin: more than just another oral glucose-lowering agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

SGLT2 mediates glucose reabsorption in the early proximal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Reducing insulin resistance with metformin: the evidence today

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effects of thiazolidinediones and sulfonylureas in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

21 January 2018

Diabetes in older adults

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1121235

10.1517/14656566.2016.1121235

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference